Yes, it will definitely trade lower. Somewhat of a bad call by the underwriters, but their hefty fees will offset any loss.
This one is being re-rated in the $4 to $5 range. Other drugs are crowding this space, and the prospects look a bit grim, really. I see this as trading around $4 until the drug is approved (then maybe $6 - $7) or delayed ($1.50 - $2.50) or lacks efficacy ($0.50 - $1).
entitlement offer closed today, page-2
Add PGL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
44.5¢ |
Change
0.005(1.14%) |
Mkt cap ! $73.28M | |||
| Open | High | Low | Value | Volume |
| 44.5¢ | 44.5¢ | 44.3¢ | $80.11K | 180.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 1146107 | 44.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 44.5¢ | 27187 | 1 |
View Market Depth
| Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
| PGL (ASX) Chart |